Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia

References

• Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506
   PubMed Web of Science ®Google Scholar
• Parisi E, Draznin J, Stoopler E, Schuster S J, Porter D, Sollecito T P. Acute myelogenous leukemia: advances and limitations of treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 257–263
   PubMed Web of Science ®Google Scholar
• Woods W G, Neudorf S, Gold S, Sanders J, Buckley J D, Barnard D R, , Children's Cancer Group, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56–62
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Rowley J D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780–2786
   PubMed Web of Science ®Google Scholar
• Brozek I, Babinska M, Kardas I, Wozniak A, Balcerska A, Hellmann A, et al. Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia. J Appl Genet 2003; 44: 401–412
   PubMed Web of Science ®Google Scholar
• Smith S M, Le Beau M M, Huo D, Karrison T, Sobecks R M, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52
   PubMed Web of Science ®Google Scholar
• Pui C H, Relling M V, Rivera G K, Hancock M L, Raimondi S C, Heslop H E, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9: 1990–1996
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients—report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963–971
   PubMed Web of Science ®Google Scholar
• Helenglass G, Powles R L, McElwain T J, Lakhani A, Milan S, Gore M, et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21–29
   PubMed Web of Science ®Google Scholar
• Anderson J E, Appelbaum F R, Schoch G, Gooley T, Anasetti C, Bensinger W I, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226
   PubMed Web of Science ®Google Scholar
• Dusenbery K E, Steinbuch M, McGlave P B, Ramsay N K, Blazar B R, Neglia J P, et al. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience. Int J Radiat Oncol Biol Phys 1996; 36: 335–343
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission. Bone Marrow Transplant 1996; 18: 119–123
   PubMed Web of Science ®Google Scholar
• Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R, , Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Haematol 1996; 93: 637–645
   PubMed Web of Science ®Google Scholar
• Michallet M, Thomas X, Vernant J P, Kuentz M, Socie G, Esperou-Bourdeau H, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157–1163
   PubMed Web of Science ®Google Scholar
• Clift R A, Buckner C D, Appelbaum F R, Bearman S I, Petersen F B, Fisher L D, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871
   PubMed Web of Science ®Google Scholar
• Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001; 27: 1189–1195
   PubMed Web of Science ®Google Scholar
• Gorin N C, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, et al. Retrospective evaluation of autologous bone marrow transplantation versus allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia: a study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 18: 111–117
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V, Stubbings H. Intensified myeloablative therapy and autologous stem-cell transplantation for patients with AML: single center experience. Cytotherapy 2003; 5: 139–146
   PubMed Web of Science ®Google Scholar
• Bartlett M L, Webb M, Durrant S, Morton A J, Allison R, Macfarlane D J. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med Mol Imaging 2002; 29: 1470–1477
   PubMed Web of Science ®Google Scholar
• Turner J H, Claringbold P G, Berger J D, Martindale A A, Glancy J R. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl Med Commun 1992; 13: 321–329
   PubMed Web of Science ®Google Scholar
• Goeckeler W F, Troutner D E, Volkert W A, Edwards B, Simon J, Wilson D. 153Sm radiotherapeutic bone agents. Int J Rad Appl Instrum B 1986; 13: 479–482
   PubMedGoogle Scholar
• Turner J H, Martindale A A, Sorby P, Hetherington E L, Fleay R F, Hoffman R F, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15: 784–795
   PubMedGoogle Scholar
• Bayouth J E, Macey D J, Kasi L P, Fossella F V. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35: 63–69
   PubMed Web of Science ®Google Scholar
• Serafini A N. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88(Suppl)2934–2939
   PubMedGoogle Scholar
• Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin 1999; 38: 337–340
   PubMedGoogle Scholar
• Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 2001; 40: 215–220
   PubMedGoogle Scholar
• Franzius C, Schuck A, Bielack S S. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 1953–1954
   PubMed Web of Science ®Google Scholar
• Anderson P M, Wiseman G A, Dispenzieri A, Arndt C A, Hartmann L C, Smithson W A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 189–196
   PubMed Web of Science ®Google Scholar
• Hogan W J, Lacy M Q, Wiseman G A, Fealey R D, Dispenzieri A, Gertz M A. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant 2001; 28: 305–309
   PubMed Web of Science ®Google Scholar
• Macfarlane D J, Durrant S, Bartlett M L, Allison R, Morton A J. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23: 1099–1106
   PubMed Web of Science ®Google Scholar
• Peylan-Ramu N, Shapira M Y, Amir G, Klein M, Chisin R, Slavin S, et al. High dose 153-samarium-EDTMP followed by non-myeloablative allogeneic stem cell transplantation in resistant hematological malignancies [abstract]. Prog Proc Am Soc Clin Oncol 2003; 22: 839
   Google Scholar
• Wiseman G A, Dispenzieri A, Anderson P M. Phase I high dose 153Samarium ethylenediaminetetramethylenephosphonoate (153-Sm EDTMP) and melphalan therapy of multiple myeloma (MM) with peripheral blood stem cell (PBSC) support [abstract]. J Nucl Med 2001; 42: 155P
   Web of Science ®Google Scholar
• Dispenzieri A, Wiseman G A, Lacy M Q, Litzow M R, Anderson P M, Gastineau D A, et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118–125
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Erlandson L, Arndt C A, Wiseman G A, Anderson P M. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant 2005; 9: 122–126
   PubMed Web of Science ®Google Scholar
• Inverardi L, Linetsky E, Pileggi A, Molano R D, Serafini A, Paganelli G, et al. Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness. Transplantation 2004; 77: 647–655
   PubMed Web of Science ®Google Scholar
• Bernstein I D. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000; 14: 474–475
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Petersdorf S H, Maloney D G, Eary J F, Wood B L, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162
   PubMed Web of Science ®Google Scholar
• Gopal A K, Gooley T A, Maloney D G, Petersdorf S H, Eary J F, Rajendran J G, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357
   PubMed Web of Science ®Google Scholar
• Jurcic J G. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm 2000; 15: 319–326
   PubMed Web of Science ®Google Scholar
• Matthews D C, Appelbaum F R, Eary J F, Fisher D R, Durack L D, Bush S A, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85: 1122–1131
   PubMed Web of Science ®Google Scholar
• Matthews D C, Appelbaum F R, Press O W, Eary J F, Bernstein I D. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. Cancer Treat Res 1997; 77: 121–139
   PubMedGoogle Scholar
• Matthews D C, Appelbaum F R, Eary J F, Fisher D R, Durack L D, Hui T E, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237–1247
   PubMed Web of Science ®Google Scholar
• Copelan E A, Penza S L, Elder P J, Belt P S, Scholl M D, Hehmeyer D M, et al. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia. Bone Marrow Transplant 1996; 18: 907–911
   PubMed Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M, Goldman J M, Kersey J, Kolb H J, et al. Graft-vs.-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Sandmaier B, Brown P A, Kaplan D, Ketring A R, Goeckeler W F, et al. Myelosuppression and mechanism of recovery following administration of 153Samarium-EDTMP. Antibody Immunoconjugates Radiopharm 1988; 1: 263–270
   Google Scholar
• Bonetti F, Montagna D, Porta F, Lanfranchi A, Zecca M, Comoli P, et al. Autologous bone marrow transplantation for acute myeloid leukaemia in children using total body irradiation and melphalan as conditioning regimen. Leukemia 1995; 9: 570–575
   PubMed Web of Science ®Google Scholar
• Maraninchi D, Pico J L, Hartmann O, Gastaut J A, Kamioner D, Hayat M, et al. High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias. Cancer Treat Rep 1986; 70: 445–448
   PubMedGoogle Scholar
• Cesaro S, Meloni G, Messina C, Pillon M, Proglia A, Lanino E, , Italian Pediatric Group for Bone Marrow Transplantation, et al. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Bone Marrow Transplant 2001; 28: 131–136
   PubMed Web of Science ®Google Scholar
• Giralt S, Thall P F, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637
   PubMed Web of Science ®Google Scholar
• Lynch M H, Petersen F B, Appelbaum F R, Bensinger W I, Clift R A, Storb R, et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59–64
   PubMed Web of Science ®Google Scholar
• Della Volpe A, Ferreri A J, Annaloro C, Mangili P, Rosso A, Calandrino R, et al. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys 2002; 52: 483–488
   PubMed Web of Science ®Google Scholar
• Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003; 102: 2684–2691
   PubMed Web of Science ®Google Scholar
• Anderson P M, Ramsay N K, Shu X O, Rydholm N, Rogosheske J, Nicklow R, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 339–344
   PubMed Web of Science ®Google Scholar